65,437 trials
Healthy Volunteers
Primary: Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 12.6; 10.4; 5.98; 10.2 microgram per milliliter (mcg/mL)
Knee Osteoarthritis
Primary: Sensor Derived Cadence — 4.62 steps/min — p=<0.0001
Neuromuscular Blockade
Primary: Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) for Sugammadex — 13.40; 16.22; 11.50; 14.07 Hour (hr)*ug/mL
End Stage Kidney Disease
Primary: Change in COVID-19 IgG Antibody (Relative Light Units) — 2.4 relative light unit (RLU)
Small-cell Lung Cancer
Primary: Main Part: Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Independent Review Committee (IRC) — 5.5…
Childhood Stroke
Primary: Number of Participants Who Complete the Study — 5 Participants
Post Traumatic Stress Disorder
Primary: Baseline TSPO Availability — 5.11; 4.75; 5.07; 4.38 mL/cm3
Stress Urinary Incontinence
Primary: Incontinence Episode Frequency (IEF) Per 24 Hours at Baseline and Week 8 — 2.9; 2.5; 2.6; 2.0 episodes
Acne Vulgaris
Primary: Primary Change in Inflammatory Lesion Counts — -72.86; -78.83; -34.12 Percent change
HIV/AIDS
Primary: Number of Participants Achieving Appropriate Levels of Tenofovir-diphosphate (TFV-DP) at 6-month Follow-up — 78; 39 Participants
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants Who Experienced Dose-Limiting Toxcity (DLT) — 0; 0; 1; 1 Participants
Myopia
Primary: Lens Handling on Removal — 95; 94 Units on scale
Ridge Preservation
Primary: Measurements of Clinical Dimensional Changes at Alveolar Ridge 3 Months After Ridge Preservation Procedure Using L-PRF Alone, L-PRF/FDBA, and L-PRF/FDBA Layered…
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Cigarette Smoking · Nicotine Vaping
Primary: Nicotine/Tobacco Products Substitution — 12.11; 4.82; 25.28; 17.08 mg of nicotine purchased — p=0.9793